{"id":145982,"date":"2023-05-12T09:24:20","date_gmt":"2023-05-12T13:24:20","guid":{"rendered":"https:\/\/44.250.171.167\/?p=145982"},"modified":"2023-05-12T09:24:22","modified_gmt":"2023-05-12T13:24:22","slug":"dr-lal-pathlabs-ltd-q4-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy23-earnings-conference-call-insights\/","title":{"rendered":"Dr Lal PathLabs Ltd Q4 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:17:48] Rahul Agarwal from InCred Capital asked if 13-14% revenue growth can be seen next year, given the supportive base, low employee attrition, and faster growth outside Delhi NCR. Om Prakash MD said FY &#8217;23 was challenging due to attrition, COVID, and other headwinds. However, LALPATH is entering FY24 in a stronger position, with lower attrition, fixed-price increases, and COVID pressures easing. LALPATHLAB expects growth in FY24.<\/li>\n<\/ul>\n<ul>\n<li>[00:22:31] Prakash Kapadia at Anived Portfolio enquired how has the competitive landscape changed in the industry due to price hikes by new age players. Bharath Uppiliappan CEO said the industry is competitive and innovative. Incumbents and new players compete, but some new players are scaling back on deep discounts as patients realize they may not be worth it. The industry is in a transitionary phase.<\/li>\n<\/ul>\n<ul>\n<li>[00:23:10] Prakash Kapadia at Anived Portfolio asked about the impact of price hikes on revenues in FY24, if it will be in specialty, packages, or specific geographies. Bharath Uppiliappan CEO said the company has not raised prices on routine tests or packages. LALPATH has raised prices on high-end tests, which will have a 1.7% impact on revenue this quarter and a 2.5% impact going forward.<\/li>\n<\/ul>\n<ul>\n<li>[00:23:29] Prakash Kapadia at Anived Portfolio asked about the key drivers for organic growth in FY24 and beyond. Bharath Uppiliappan CEO replied that LALPATH plans to grow its business by expanding into Tier-3 and Tier-4 cities, strengthening its presence in metro cities, and differentiating its channel management programs. LALPATH will also focus on high-end testing, such as genomic testing and Centers of Excellence, and on improving tech stack to provide a better patient experience.<\/li>\n<\/ul>\n<ul>\n<li>[00:30:01] Bino Pathiparampil at Elara Capital asked about the plans for addition of labs for FY24 and FY25. Bharath Uppiliappan CEO replied that the company will continue to expand its lab network by opening 10-15 new labs in Tier-3 and Tier-4 cities in the North-East, South, and West.<\/li>\n<\/ul>\n<ul>\n<li>[00:30:37] Lavanya from UBS enquired about the margins for suburban in 4Q23 as last quarter there was a meaningful hit. Bharath Uppiliappan CEO replied that normalized EBITDA margins for suburban for 4Q23 is about 11.2% and for full year it is 12%.<\/li>\n<\/ul>\n<ul>\n<li>[00:33:45] Prakash Agarwal from Axis Capital asked how has the price increase for specialized tests affected LALPATH business. Bharath Uppiliappan CEO replied that the price increase for specialized tests has gone relatively well. The compa also did not raise prices on routine tests or packages. We expect that other companies will also raise prices in the coming months, due to inflation and the lowering of COVID volumes.<\/li>\n<\/ul>\n<ul>\n<li>[00:36:01] Prakash Agarwal from Axis Capital enquired how has the competitive environment in the B2B segment changed, and how is LALPATH performing in the South. Bharath Uppiliappan CEO said the B2B segment is as competitive as ever, but the company has put in place multiple programs to manage it effectively. B2B is LALPATH\u2019s fastest-growing channels today, and is pleased with the progress of its channel management program. LALPATH is also continuing to grow its business in the South at a faster rate than the company as a whole.<\/li>\n<\/ul>\n<ul>\n<li>[00:39:09] Nitin Agarwal with DAM Capital asked that despite the growing business, how there has been a reduction in employee costs and other expenses. Bharath Uppiliappan CEO said the use of technology has helped the company automate its processes and reduce headcount.<\/li>\n<\/ul>\n<ul>\n<li>[00:45:52] Cyndrella Carvalho from JM Financial asked that Mumbai lab has been a good source of patient growth in the past, so how do will it continue to contribute to overall patient growth in future. Shankha Banerjee CEO replied that the Mumbai lab was launched in Jan. and is expected to take longer to reach its full potential than LALPATH\u2019s other reference labs. This is because it is targeting a new customer base and a new vertical. However, the company expects it to have a positive impact on patient growth in the coming quarters.<\/li>\n<\/ul>\n<ul>\n<li>[00:47:35] Cyndrella Carvalho from JM Financial asked if LALPATH\u2019s cost base will support its growth and operating leverage in FY24 and FY25. Ved Prakash Goel Group CFO said that the new reference lab will give the company a competitive advantage and that its existing infrastructure can be leveraged to improve margins.<\/li>\n<\/ul>\n<ul>\n<li>[00:49:03] Tanmay Gandhi of Investec asked why was the sequential growth flat in 4Q23, when it has historically been between 3% and 5%. Om Prakash MD said sequential growth has been flat in 4Q for the past two years. It\u2019s attributed to factors like evening out of infection rates and the increase in screening packages due to air pollution. LALPATH is hopeful that FY24 will be different, as COVID will no longer be a variable.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY23 Earnings Concall Q&amp;A Highlights: [00:17:48] Rahul Agarwal from InCred Capital asked if 13-14% revenue growth can be seen next year, given the supportive base, low employee attrition, and faster growth outside Delhi NCR. Om Prakash MD said FY &#8217;23 was challenging due to attrition, COVID, [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Dr Lal PathLabs Ltd Q4 FY23 Earnings Conference Call Insights #LALPATHLAB #Q4 #FY23 #Earnings #Stocks ","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[8665,10169,8160],"class_list":["post-145982","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-diagnostics","tag-earnings","tag-healthcare-services"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":132298,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":145982,"position":0},"title":"Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 3, 2022","format":false,"excerpt":"https:\/\/youtu.be\/GyHJJGLWdjg Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Management Update: LALPATHLAB said it clocked the highest quarterly non-COVID revenue of INR482 crore, a growth of 25% YoYs. Additionally, COVID revenue significantly declined by 91% from INR221 crore to INR21 crore in 1Q23. Q&A Highlights: Pooja\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":140051,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":145982,"position":1},"title":"Dr Lal PathLabs Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 3, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:12:28] Dheeresh Pathak from WhiteOak asked about the revenue and EBITDA for Suburban for 3Q23. C. A. Ved Prakash CFO said Suburban had revenue of INR37 crores, with INR35 crores from non-COVID and the rest from\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":129608,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":145982,"position":2},"title":"Dr Lal PathLabs Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 18, 2022","format":false,"excerpt":"https:\/\/youtu.be\/XGfFd6kLFCE Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Management Update: LALPATHLAB said it saw significant shift towards direct-to-home business, with home collections now contributing nearly 12%, which used to be in the range of 5-6% during pre-COVID days. Also the company saw bundled packages continuing\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":136294,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":145982,"position":3},"title":"Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 10, 2022","format":false,"excerpt":"https:\/\/youtu.be\/lAaNZKEvjOc Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:43] Rahul Agarwal with Incred Capital enquired about 2Q23 performance according to the company\u2019s expectations. Arvind Lal EC said the company\u2019s opinion is that the performance is slightly in line with what it was doing\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139887,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-limited-q3-fy23-net-profit-down-by-8\/","url_meta":{"origin":145982,"position":4},"title":"Dr. Lal PathLabs Limited Q3 FY23; Net Profit  Down By 8%","author":"Hardik Bhandare","date":"February 2, 2023","format":false,"excerpt":"Dr. Lal PathLabs Limited (NSE: LALPATHLAB) reported a Revenue from Operations of \u20b9489.4 Crores, a decline of 1.5% from the previous year. The Consolidated Net Profit for the business also decreased by 8% year over year, to \u20b953.6 Crore from \u20b958.2 Crore. Earnings per Share is \u20b96.35 for this quarter.","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":132319,"url":"https:\/\/alphastreet.com\/india\/earnings-infographic-dr-lal-pathlabs-q1-2023-revenue-and-profit-decline\/","url_meta":{"origin":145982,"position":5},"title":"Earnings Infographic: Dr. Lal PathLabs Q1 2023 revenue and profit decline","author":"Manoj_Nair","date":"August 3, 2022","format":false,"excerpt":"Dr. Lal PathLabs Ltd (NSE: LALPATHLAB), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for the first quarter of 2023. The company also announced an interim dividend of \u20b96 per share. First-quarter revenues dropped 17% year-over-year to \u20b9502.7 crores, hurt by a sharp\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/145982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=145982"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/145982\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=145982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=145982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=145982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}